UK markets open in 2 hours 2 minutes

Sanofi (0A2V.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
49.56-0.51 (-1.02%)
At close: 07:00PM BST
Full screen
Previous close50.07
BidN/A x N/A
AskN/A x N/A
Day's range49.18 - 49.28
52-week range36.99 - 57.78
Avg. volume20,422
Market capN/A
Beta (5Y monthly)0.42
PE ratio (TTM)N/A
Earnings date25 Jul 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Simply Wall St.

    Exploring Three Top Dividend Stocks On Euronext Paris

    In recent trading sessions, the French stock market has shown resilience, with the CAC 40 Index modestly increasing by 0.11%. This uptick reflects cautious optimism among investors following the European Central Bank's decision to cut interest rates for the first time in five years, signaling a potentially more supportive environment for equities. In this context, dividend stocks can be particularly appealing as they offer potential income in addition to price appreciation opportunities...

  • GlobeNewswire

    Sanofi: Information concerning the total number of voting rights and shares – May 2024

    Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,529,599,938 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regi

  • PR Newswire

    I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

    I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team.